The US firm develops a therapeutic solution for resistant hypertension, for which there is no effective treatment.
The venture capital manager Ysios Capital, specialized in the biotechnology sector, has participated in a round of financing of 118 million dollars (110 million euros) from the US firm Mineralys Therapeutics. The company develops
